Vor Biopharma INC Form 4 insider transactions

Director Fouad Namouni acquired 30,000 stock options in Vor Biopharma Inc. on May 23, 2024, according to a Form 4 filing.

Director Daniella Beckman of Vor Biopharma Inc. reports the acquisition of 30,000 stock options at an exercise price of $1.61.

Director Sven Ante Lundberg acquired 30,000 stock options in Vor Biopharma Inc. on May 23, 2024, according to a recent SEC filing.

Director David Charles Lubner acquired stock options for 30,000 shares of Vor Biopharma Inc. at an exercise price of $1.61 on May 23, 2024.

Matthew R. Patterson, a director of Vor Biopharma Inc., acquired 30,000 stock options on May 23, 2024, as part of the company's non-employee director compensation policy.

Director Joshua Resnick received stock options for 30,000 shares of Vor Biopharma Inc. (VOR) common stock.

RA Capital Management and related entities report the acquisition of stock options in Vor Biopharma Inc. on behalf of Joshua Resnick, a director, under a non-employee director compensation policy.

CFO of Vor Biopharma, Nathan D. Jorgensen, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., disposed of 875 shares of common stock on May 6, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Vor Biopharma's CEO, Robert Ang, disposed of 2,361 shares of common stock on May 6, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Vor Biopharma CEO Robert Ang disposed of 2,751 shares of common stock on May 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reports the disposal of 1,146 shares of common stock to cover tax obligations related to restricted stock units.

Nathan Jorgensen, CFO of Vor Biopharma Inc., reports the disposition of 917 common stock shares to cover tax withholding obligations related to restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., sold 985 shares of common stock on May 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Director Fouad Namouni acquired 60,000 stock options in Vor Biopharma Inc. on April 30, 2024.

Vor Biopharma's CFO, Nathan D. Jorgensen, disposed of 6,310 shares of common stock to cover tax withholding obligations related to the settlement of restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer of Vor Biopharma Inc., sold 5,576 shares of common stock on March 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.

Vor Biopharma CEO Robert Ang sold 12,657 shares of common stock on March 1, 2024, to cover tax obligations related to the settlement of restricted stock units.